Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 251

1.

Analysis of human leukocyte antigen allele polymorphism in patients with non alcoholic fatty liver disease.

Karrar A, Hariharan S, Fazel Y, Moosvi A, Houry M, Younoszai Z, Jeffers T, Zheng L, Munkhzul O, Hunt S, Monge F, Goodman Z, Younossi ZM.

Medicine (Baltimore). 2019 Aug;98(32):e16704. doi: 10.1097/MD.0000000000016704.

2.

Noninvasive Tests Accurately Identify Advanced Fibrosis due to NASH: Baseline Data From the STELLAR Trials.

Anstee QM, Lawitz EJ, Alkhouri N, Wong VW, Romero-Gomez M, Okanoue T, Trauner M, Kersey K, Li G, Han L, Jia C, Wang L, Chen G, Subramanian GM, Myers RP, Djedjos CS, Kohli A, Bzowej N, Younes Z, Sarin S, Shiffman ML, Harrison SA, Afdhal NH, Goodman Z, Younossi ZM.

Hepatology. 2019 Nov;70(5):1521-1530. doi: 10.1002/hep.30842. Epub 2019 Aug 19.

PMID:
31271665
3.

REGENERATE: Design of a pivotal, randomised, phase 3 study evaluating the safety and efficacy of obeticholic acid in patients with fibrosis due to nonalcoholic steatohepatitis.

Ratziu V, Sanyal AJ, Loomba R, Rinella M, Harrison S, Anstee QM, Goodman Z, Bedossa P, MacConell L, Shringarpure R, Shah A, Younossi Z.

Contemp Clin Trials. 2019 Sep;84:105803. doi: 10.1016/j.cct.2019.06.017. Epub 2019 Jun 29.

4.

The Natural History of Advanced Fibrosis Due to Nonalcoholic Steatohepatitis: Data From the Simtuzumab Trials.

Sanyal AJ, Harrison SA, Ratziu V, Abdelmalek MF, Diehl AM, Caldwell S, Shiffman ML, Aguilar Schall R, Jia C, McColgan B, Djedjos CS, McHutchison JG, Subramanian GM, Myers RP, Younossi Z, Muir AJ, Afdhal NH, Bosch J, Goodman Z.

Hepatology. 2019 Apr 16. doi: 10.1002/hep.30664. [Epub ahead of print]

PMID:
30993748
5.

Reduced Patient-Reported Outcome Scores Associate With Level of Fibrosis in Patients With Nonalcoholic Steatohepatitis.

Younossi ZM, Stepanova M, Anstee QM, Lawitz EJ, Wai-Sun Wong V, Romero-Gomez M, Kersey K, Li G, Subramanian GM, Myers RP, Djedjos CS, Okanoue T, Trauner M, Goodman Z, Harrison SA.

Clin Gastroenterol Hepatol. 2019 Nov;17(12):2552-2560.e10. doi: 10.1016/j.cgh.2019.02.024. Epub 2019 Feb 16.

PMID:
30779990
6.

Hepatic sonic hedgehog protein expression measured by computer assisted morphometry significantly correlates with features of non-alcoholic steatohepatitis.

Estep M, Mehta R, Bratthauer G, Alaparthi L, Monge F, Ali S, Abdelatif D, Younoszai Z, Stepanova M, Goodman ZD, Younossi ZM.

BMC Gastroenterol. 2019 Feb 11;19(1):27. doi: 10.1186/s12876-019-0951-y.

7.

Morphometry Confirms Fibrosis Regression From Sustained Virologic Response to Direct-Acting Antivirals for Hepatitis C.

Pan JJ, Bao F, Du E, Skillin C, Frenette CT, Waalen J, Alaparthi L, Goodman ZD, Pockros PJ.

Hepatol Commun. 2018 Sep 21;2(11):1320-1330. doi: 10.1002/hep4.1228. eCollection 2018 Nov.

8.

Longitudinal correlations between MRE, MRI-PDFF, and liver histology in patients with non-alcoholic steatohepatitis: Analysis of data from a phase II trial of selonsertib.

Jayakumar S, Middleton MS, Lawitz EJ, Mantry PS, Caldwell SH, Arnold H, Mae Diehl A, Ghalib R, Elkhashab M, Abdelmalek MF, Kowdley KV, Stephen Djedjos C, Xu R, Han L, Mani Subramanian G, Myers RP, Goodman ZD, Afdhal NH, Charlton MR, Sirlin CB, Loomba R.

J Hepatol. 2019 Jan;70(1):133-141. doi: 10.1016/j.jhep.2018.09.024. Epub 2018 Oct 4.

9.

Liver Biopsy in Primary Biliary Cholangitis: Indications and Interpretation.

Tan D, Goodman ZD.

Clin Liver Dis. 2018 Aug;22(3):579-588. doi: 10.1016/j.cld.2018.03.008. Review.

PMID:
30259854
10.

Intrahepatic Reactive Lymphoid Hyperplasia: A Case Report and Review of the Literature.

Seitter S, Goodman ZD, Friedman TM, Shaver TR, Younan G.

Case Rep Surg. 2018 Sep 6;2018:9264251. doi: 10.1155/2018/9264251. eCollection 2018.

11.

An exploratory study examining how nano-liquid chromatography-mass spectrometry and phosphoproteomics can differentiate patients with advanced fibrosis and higher percentage collagen in non-alcoholic fatty liver disease.

Younossi ZM, Karrar A, Pierobon M, Birerdinc A, Stepanova M, Abdelatif D, Younoszai Z, Jeffers T, Felix S, Jeiran K, Hodge A, Zhou W, Monge F, Alaparthi L, Chandhoke V, Goodman ZD, Petricoin EF.

BMC Med. 2018 Sep 12;16(1):170. doi: 10.1186/s12916-018-1136-1.

12.

Assessment of liver fibrosis progression and regression by a serological collagen turnover profile.

Karsdal MA, Hjuler ST, Luo Y, Rasmussen DGK, Nielsen MJ, Holm Nielsen S, Leeming DJ, Goodman Z, Arch RH, Patel K, Schuppan D.

Am J Physiol Gastrointest Liver Physiol. 2019 Jan 1;316(1):G25-G31. doi: 10.1152/ajpgi.00158.2018. Epub 2018 Aug 30.

PMID:
30160980
13.

Simtuzumab for Primary Sclerosing Cholangitis: Phase 2 Study Results With Insights on the Natural History of the Disease.

Muir AJ, Levy C, Janssen HLA, Montano-Loza AJ, Shiffman ML, Caldwell S, Luketic V, Ding D, Jia C, McColgan BJ, McHutchison JG, Mani Subramanian G, Myers RP, Manns M, Chapman R, Afdhal NH, Goodman Z, Eksteen B, Bowlus CL; GS-US-321-0102 Investigators.

Hepatology. 2019 Feb;69(2):684-698. doi: 10.1002/hep.30237. Epub 2019 Jan 11.

PMID:
30153359
14.

The conundrum of cryptogenic cirrhosis: Adverse outcomes without treatment options.

Younossi Z, Stepanova M, Sanyal AJ, Harrison SA, Ratziu V, Abdelmalek MF, Diehl AM, Caldwell S, Shiffman ML, Schall RA, McColgan B, Subramanian GM, Myers RP, Muir A, Afdhal NH, Bosch J, Goodman Z.

J Hepatol. 2018 Dec;69(6):1365-1370. doi: 10.1016/j.jhep.2018.08.013. Epub 2018 Aug 23.

PMID:
30144554
15.

Liver Transplantation (LT) for Cryptogenic Cirrhosis (CC) and Nonalcoholic Steatohepatitis (NASH) Cirrhosis: Data from the Scientific Registry of Transplant Recipients (SRTR): 1994 to 2016.

Golabi P, Bush H, Stepanova M, Locklear CT, Jacobson IM, Mishra A, Trimble G, Erario M, Venkatesan C, Younossi I, Goodman Z, Younossi ZM.

Medicine (Baltimore). 2018 Aug;97(31):e11518. doi: 10.1097/MD.0000000000011518.

16.

Simtuzumab Is Ineffective for Patients With Bridging Fibrosis or Compensated Cirrhosis Caused by Nonalcoholic Steatohepatitis.

Harrison SA, Abdelmalek MF, Caldwell S, Shiffman ML, Diehl AM, Ghalib R, Lawitz EJ, Rockey DC, Schall RA, Jia C, McColgan BJ, McHutchison JG, Subramanian GM, Myers RP, Younossi Z, Ratziu V, Muir AJ, Afdhal NH, Goodman Z, Bosch J, Sanyal AJ; GS-US-321-0105 and GS-US-321-0106 Investigators.

Gastroenterology. 2018 Oct;155(4):1140-1153. doi: 10.1053/j.gastro.2018.07.006. Epub 2018 Jul 7.

PMID:
29990488
17.

Polymorphisms in the receptor for advanced glycation end-products (RAGE) gene and circulating RAGE levels as a susceptibility factor for non-alcoholic steatohepatitis (NASH).

Mehta R, Shaw G, Masschelin P, Felix S, Otgonsuren M, Baranova A, Goodman Z, Younossi Z.

PLoS One. 2018 Jun 21;13(6):e0199294. doi: 10.1371/journal.pone.0199294. eCollection 2018.

18.

Nonalcoholic steatofibrosis independently predicts mortality in nonalcoholic fatty liver disease.

Younossi ZM, Stepanova M, Rafiq N, Henry L, Loomba R, Makhlouf H, Goodman Z.

Hepatol Commun. 2017 Jun 6;1(5):421-428. doi: 10.1002/hep4.1054. eCollection 2017 Jul.

19.

Improvement of hepatic fibrosis and patient-reported outcomes in non-alcoholic steatohepatitis treated with selonsertib.

Younossi ZM, Stepanova M, Lawitz E, Charlton M, Loomba R, Myers RP, Subramanian M, McHutchison JG, Goodman Z.

Liver Int. 2018 Oct;38(10):1849-1859. doi: 10.1111/liv.13706. Epub 2018 Feb 22.

PMID:
29377462
20.

DNA methylation signatures reflect aging in patients with nonalcoholic steatohepatitis.

Loomba R, Gindin Y, Jiang Z, Lawitz E, Caldwell S, Djedjos CS, Xu R, Chung C, Myers RP, Subramanian GM, Goodman Z, Charlton M, Afdhal NH, Diehl AM.

JCI Insight. 2018 Jan 25;3(2). pii: 96685. doi: 10.1172/jci.insight.96685. eCollection 2018 Jan 25.

21.

cHCC-CCA: Consensus terminology for primary liver carcinomas with both hepatocytic and cholangiocytic differentation.

Brunt E, Aishima S, Clavien PA, Fowler K, Goodman Z, Gores G, Gouw A, Kagen A, Klimstra D, Komuta M, Kondo F, Miksad R, Nakano M, Nakanuma Y, Ng I, Paradis V, Nyun Park Y, Quaglia A, Roncalli M, Roskams T, Sakamoto M, Saxena R, Sempoux C, Sirlin C, Stueck A, Thung S, Tsui WMS, Wang XW, Wee A, Yano H, Yeh M, Zen Y, Zucman-Rossi J, Theise N.

Hepatology. 2018 Jul;68(1):113-126. doi: 10.1002/hep.29789. Epub 2018 May 9.

22.

Diagnostic modalities for nonalcoholic fatty liver disease, nonalcoholic steatohepatitis, and associated fibrosis.

Younossi ZM, Loomba R, Anstee QM, Rinella ME, Bugianesi E, Marchesini G, Neuschwander-Tetri BA, Serfaty L, Negro F, Caldwell SH, Ratziu V, Corey KE, Friedman SL, Abdelmalek MF, Harrison SA, Sanyal AJ, Lavine JE, Mathurin P, Charlton MR, Goodman ZD, Chalasani NP, Kowdley KV, George J, Lindor K.

Hepatology. 2018 Jul;68(1):349-360. doi: 10.1002/hep.29721.

23.

Current and future therapeutic regimens for nonalcoholic fatty liver disease and nonalcoholic steatohepatitis.

Younossi ZM, Loomba R, Rinella ME, Bugianesi E, Marchesini G, Neuschwander-Tetri BA, Serfaty L, Negro F, Caldwell SH, Ratziu V, Corey KE, Friedman SL, Abdelmalek MF, Harrison SA, Sanyal AJ, Lavine JE, Mathurin P, Charlton MR, Chalasani NP, Anstee QM, Kowdley KV, George J, Goodman ZD, Lindor K.

Hepatology. 2018 Jul;68(1):361-371. doi: 10.1002/hep.29724.

24.

The ASK1 inhibitor selonsertib in patients with nonalcoholic steatohepatitis: A randomized, phase 2 trial.

Loomba R, Lawitz E, Mantry PS, Jayakumar S, Caldwell SH, Arnold H, Diehl AM, Djedjos CS, Han L, Myers RP, Subramanian GM, McHutchison JG, Goodman ZD, Afdhal NH, Charlton MR; GS-US-384-1497 Investigators.

Hepatology. 2018 Feb;67(2):549-559. doi: 10.1002/hep.29514. Epub 2017 Dec 26. Erratum in: Hepatology. 2018 May;67(5):2063.

25.

A randomized, placebo-controlled trial of cenicriviroc for treatment of nonalcoholic steatohepatitis with fibrosis.

Friedman SL, Ratziu V, Harrison SA, Abdelmalek MF, Aithal GP, Caballeria J, Francque S, Farrell G, Kowdley KV, Craxi A, Simon K, Fischer L, Melchor-Khan L, Vest J, Wiens BL, Vig P, Seyedkazemi S, Goodman Z, Wong VW, Loomba R, Tacke F, Sanyal A, Lefebvre E.

Hepatology. 2018 May;67(5):1754-1767. doi: 10.1002/hep.29477. Epub 2018 Jan 29.

26.

Cardiovascular Response to Recreational Hockey in Middle-Aged Men.

Goodman ZA, Thomas SG, Wald RC, Goodman JM.

Am J Cardiol. 2017 Jun 15;119(12):2093-2097. doi: 10.1016/j.amjcard.2017.03.241. Epub 2017 Apr 11.

PMID:
28438305
27.

Characterization of HCV NS3 Protease Variants in HCV/HIV-Coinfected Patients by Ultra-Deep Sequence Analysis: Relationship with Hepatic Fibrosis.

Abdel-Hameed EA, Rouster SD, Zhang X, Chen J, Medvedovic M, Goodman ZD, Sherman KE.

J Acquir Immune Defic Syndr. 2017 Mar 1;74(3):353-358. doi: 10.1097/QAI.0000000000001256.

28.

Phenotypes and Pathology of Drug-Induced Liver Disease.

Goodman ZD.

Clin Liver Dis. 2017 Feb;21(1):89-101. doi: 10.1016/j.cld.2016.08.006. Epub 2016 Oct 18. Review.

PMID:
27842777
29.

Fibrogenesis assessed by serological type III collagen formation identifies patients with progressive liver fibrosis and responders to a potential antifibrotic therapy.

Karsdal MA, Henriksen K, Nielsen MJ, Byrjalsen I, Leeming DJ, Gardner S, Goodman Z, Patel K, Krag A, Christiansen C, Schuppan D.

Am J Physiol Gastrointest Liver Physiol. 2016 Dec 1;311(6):G1009-G1017. doi: 10.1152/ajpgi.00283.2016. Epub 2016 Oct 20.

30.

The role of mitochondrial genomics in patients with non-alcoholic steatohepatitis (NASH).

Mehta R, Jeiran K, Koenig AB, Otgonsuren M, Goodman Z, Baranova A, Younossi Z.

BMC Med Genet. 2016 Sep 5;17(1):63. doi: 10.1186/s12881-016-0324-0.

31.

Proposals to Conduct Randomized Controlled Trials Without Informed Consent: a Narrative Review.

Flory JH, Mushlin AI, Goodman ZI.

J Gen Intern Med. 2016 Dec;31(12):1511-1518. Epub 2016 Jul 6. Review.

32.

Elastography Assessment of Liver Fibrosis: Society of Radiologists in Ultrasound Consensus Conference Statement.

Barr RG, Ferraioli G, Palmeri ML, Goodman ZD, Garcia-Tsao G, Rubin J, Garra B, Myers RP, Wilson SR, Rubens D, Levine D.

Ultrasound Q. 2016 Jun;32(2):94-107. doi: 10.1097/RUQ.0000000000000209. No abstract available.

PMID:
27233069
33.

Simtuzumab treatment of advanced liver fibrosis in HIV and HCV-infected adults: results of a 6-month open-label safety trial.

Meissner EG, McLaughlin M, Matthews L, Gharib AM, Wood BJ, Levy E, Sinkus R, Virtaneva K, Sturdevant D, Martens C, Porcella SF, Goodman ZD, Kanwar B, Myers RP, Subramanian M, Hadigan C, Masur H, Kleiner DE, Heller T, Kottilil S, Kovacs JA, Morse CG.

Liver Int. 2016 Dec;36(12):1783-1792. doi: 10.1111/liv.13177. Epub 2016 Jul 6.

34.

Long-Term Follow-Up of Children Treated With Peginterferon and Ribavirin for Hepatitis C Virus Infection.

Haber B, Alonso E, Pedreira A, Rodriguez-Baez N, Ciocca M, Lacaille F, Lang T, Gonzalez T, Goodman Z, Yang Z, Jackson B, Noviello S, Albrecht JK.

J Pediatr Gastroenterol Nutr. 2017 Jan;64(1):89-94. doi: 10.1097/MPG.0000000000001239.

PMID:
27111344
35.

mTor signaling is required for the formation of proliferating Müller glia-derived progenitor cells in the chick retina.

Zelinka CP, Volkov L, Goodman ZA, Todd L, Palazzo I, Bishop WA, Fischer AJ.

Development. 2016 Jun 1;143(11):1859-73. doi: 10.1242/dev.133215. Epub 2016 Apr 11.

36.

Epidemiology and natural history of non-alcoholic fatty liver disease.

Fazel Y, Koenig AB, Sayiner M, Goodman ZD, Younossi ZM.

Metabolism. 2016 Aug;65(8):1017-25. doi: 10.1016/j.metabol.2016.01.012. Epub 2016 Jan 29. Review.

PMID:
26997539
37.

Efficacy and safety study of cenicriviroc for the treatment of non-alcoholic steatohepatitis in adult subjects with liver fibrosis: CENTAUR Phase 2b study design.

Friedman S, Sanyal A, Goodman Z, Lefebvre E, Gottwald M, Fischer L, Ratziu V.

Contemp Clin Trials. 2016 Mar;47:356-65. doi: 10.1016/j.cct.2016.02.012. Epub 2016 Mar 2.

38.

Elevated prefrontal cortex GABA in patients with major depressive disorder after TMS treatment measured with proton magnetic resonance spectroscopy.

Dubin MJ, Mao X, Banerjee S, Goodman Z, Lapidus KA, Kang G, Liston C, Shungu DC.

J Psychiatry Neurosci. 2016 Apr;41(3):E37-45.

39.

Longitudinal assessment of hepatitis C fibrosis progression by collagen and smooth muscle actin morphometry in comparison to serum markers.

Patel K, Tillmann HL, Matta B, Sheridan MJ, Gardner SD, Shackel NA, McHutchison JG, Goodman ZD.

Aliment Pharmacol Ther. 2016 Feb;43(3):356-63. doi: 10.1111/apt.13471. Epub 2015 Nov 11.

40.

Evaluation of Liver Fibrosis Using Texture Analysis on Combined-Contrast-Enhanced Magnetic Resonance Images at 3.0T.

Yokoo T, Wolfson T, Iwaisako K, Peterson MR, Mani H, Goodman Z, Changchien C, Middleton MS, Gamst AC, Mazhar SM, Kono Y, Ho SB, Sirlin CB.

Biomed Res Int. 2015;2015:387653. doi: 10.1155/2015/387653. Epub 2015 Sep 1.

41.

A Phase 3 Trial of Sebelipase Alfa in Lysosomal Acid Lipase Deficiency.

Burton BK, Balwani M, Feillet F, Barić I, Burrow TA, Camarena Grande C, Coker M, Consuelo-Sánchez A, Deegan P, Di Rocco M, Enns GM, Erbe R, Ezgu F, Ficicioglu C, Furuya KN, Kane J, Laukaitis C, Mengel E, Neilan EG, Nightingale S, Peters H, Scarpa M, Schwab KO, Smolka V, Valayannopoulos V, Wood M, Goodman Z, Yang Y, Eckert S, Rojas-Caro S, Quinn AG.

N Engl J Med. 2015 Sep 10;373(11):1010-20. doi: 10.1056/NEJMoa1501365.

42.

Long-Term Telbivudine Treatment Results in Resolution of Liver Inflammation and Fibrosis in Patients with Chronic Hepatitis B.

Hou JL, Xu D, Shi G, Wan M, Goodman Z, Tan D, Xie Q, Chen C, Wei L, Niu J, Wang Q, Ren H, Wang Y, Jia J, Bao W, Dong Y, Trylesinski A, Naoumov NV.

Adv Ther. 2015 Aug;32(8):727-41. doi: 10.1007/s12325-015-0232-2. Epub 2015 Sep 2.

43.

What Is the Right Way to Respect Patient Perspectives?

Goodman ZI, Flory JH.

Am J Bioeth. 2015;15(9):32-3. doi: 10.1080/15265161.2015.1062176. No abstract available.

PMID:
26305749
44.

Elastography Assessment of Liver Fibrosis: Society of Radiologists in Ultrasound Consensus Conference Statement.

Barr RG, Ferraioli G, Palmeri ML, Goodman ZD, Garcia-Tsao G, Rubin J, Garra B, Myers RP, Wilson SR, Rubens D, Levine D.

Radiology. 2015 Sep;276(3):845-61. doi: 10.1148/radiol.2015150619. Epub 2015 Jun 16.

PMID:
26079489
45.

Current efforts and trends in the treatment of NASH.

Ratziu V, Goodman Z, Sanyal A.

J Hepatol. 2015 Apr;62(1 Suppl):S65-75. doi: 10.1016/j.jhep.2015.02.041. Review.

46.

Well-differentiated hepatocellular neoplasm of uncertain malignant potential--reply.

Bedossa P, Burt AD, Brunt E, Callea F, Clouston AD, Dienes HP, Goodman ZD, Gouw AS, Hubscher SG, Roberts EA, Roskams T, Terracciano L, Tiniakos DG, Torbenson MS, Wanless IR.

Hum Pathol. 2015 Apr;46(4):635-6. doi: 10.1016/j.humpath.2014.10.030. Epub 2014 Dec 31. No abstract available.

PMID:
25732109
47.

Expression of NALPs in adipose and the fibrotic progression of non-alcoholic fatty liver disease in obese subjects.

Mehta R, Neupane A, Wang L, Goodman Z, Baranova A, Younossi ZM.

BMC Gastroenterol. 2014 Dec 16;14:208. doi: 10.1186/s12876-014-0208-8.

48.

Anti-adipocyte antibody response in patients with non-alcoholic fatty liver disease.

Karrar A, Stepanova M, Alaparthi L, Lingam S, Younoszai Z, Zheng L, Malik KS, Younossi E, Monge F, Hunt SL, Goodman Z, Younossi ZM.

J Gastroenterol Hepatol. 2015 May;30(5):900-8. doi: 10.1111/jgh.12856.

PMID:
25469790
49.

Correlates of adiponectin in hepatitis C-infected children: the importance of body mass index.

Delgado-Borrego A, Gonzalez-Peralta RP, Raza R, Negre B, Goodman ZD, Jonas MM, Chung RT, Ludwig DA; PEDS-C Clinical Research Network.

J Pediatr Gastroenterol Nutr. 2015 Feb;60(2):165-70. doi: 10.1097/MPG.0000000000000604.

PMID:
25313851
50.

Plasma Pro-C3 (N-terminal type III collagen propeptide) predicts fibrosis progression in patients with chronic hepatitis C.

Nielsen MJ, Veidal SS, Karsdal MA, Ørsnes-Leeming DJ, Vainer B, Gardner SD, Hamatake R, Goodman ZD, Schuppan D, Patel K.

Liver Int. 2015 Feb;35(2):429-37. doi: 10.1111/liv.12700. Epub 2014 Oct 29.

PMID:
25308921

Supplemental Content

Loading ...
Support Center